Abstract:Abstract Background：Postsynaptic density 93 (PSD-93) plays an important role in ischemic brain injury through mediating neurotoxicity and neuroinflammation. Blocked the combination of PSD-93 and Fractalkine (CX3Cchemokineligand1, CX3CL1) play beneficial roles in acute ischemic stroke. However, the underlying mechanism still need further exploration. Methods：In this study, male C57BL/6 mice aged 8-12 weeks and weighted 22-26g were applied with Middle Cerebral Artery Occlusion (MCAO) model and randomly divided into different groups. Firstly, real-time quantitative PCR was to detect some cytokines associated with M1 and M2 type of microglia at different time points in transient MCAO model. Secondly, triphenyl tetrazolium chloride (TTC) staining, brain water content and behavioral assessments were used to evaluate the neurologic damage. Immunofluorescence staining was performed to measure the white matter injury, and microglia polarization. Moreover, enzyme-linked immunosorbent assay (ELISA) was used to investigate the expression of soluble CX3CL1. Results：M1 phenotype cytokines were detected at different time points and found that their expression increased from beginning at 6 hours after reperfusion and most peaked at 24 h after reperfusion. However, the expression of M2 phenotype cytokines decreased or still keep invariant at 6 hours and 24 h after reperfusion. Interestingly, Tat-CX3CL1 (357-395aa) can facilitate microglia polarization from M1 type to M2 type through inhibiting expression of the soluble CX3CL1. Furthermore, CX3CL1 specific cleavase inhibitor ADAM17 could restrain the microglia polarization transformation via reducing the soluble CX3CL1 formation. Moreover, Tat-CX3CL1 (357-395aa) also attenuate long-term cognitive deficits and improved white matter integrity. Conclusions: In conclusion, we demonstrated that specific blockage the binding of PSD-93 and CX3CL1 by Tat-CX3CL1 (357-395aa) could perform functional recovery after ischemic stroke by promoting type microglia polarization transformation from M1 to M2. And the peptide Tat-CX3CL1 (357-395aa) is a promising strategy for treatment of ischemic stroke.

Blocking PSD-93-CX3CL1 Interaction Promotes Phenotypic Polarization Transformation of Microglia During Acute Ischemic Stroke Injury